Dermatology Doctors in Andover, MA Accepting Medicare

3 Dermatology doctors found. Showing 1 - 3

Christine H Andersen, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 138 Haverhill St, Suite 200, Andover, MA 01810 Phone: 978-475-4322    Fax: 978-474-4537

Mr. David M Gruber, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 138 Haverhill St, Suite 200, Andover, MA 01810 Phone: 978-475-4322    Fax: 978-474-4537

Michael J Terlizzi, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 138 Haverhill St, Suite 200, Andover, MA 01810 Phone: 978-475-4322    Fax: 978-474-4537

News Archive

People who do shiftwork are more likely to have diet that promotes chronic inflammation

People who do shiftwork are more likely to have a diet that promotes chronic inflammation—which may partly explain the health risks associated with shiftwork, reports a study in the February Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

Disabled children in West Africa face greater risk of violence, study finds

Disabled children in West Africa experience significantly greater violence than their non-disabled peers and all experience violence from they day they are born, finds a study published in BMC Public Health by Janet Njelesani, assistant professor of occupational therapy at NYU Steinhardt School of Culture, Education, and Human Development.

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

Screening for Clostridium difficile before hospital admission could cut infection rates

Screening people for Clostridium difficile before they are admitted to hospital may be one way to help control rising rates of infection, says a doctor in the British Medical Journal.

Read more Medical News

› Verified 9 days ago